Imaging and fluid biomarkers in frontotemporal dementia

Nature Reviews Neurology, Journal Year: 2017, Volume and Issue: 13(7), P. 406 - 419

Published: June 16, 2017

Language: Английский

---

Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration

Neuron, Journal Year: 2016, Volume and Issue: 91(1), P. 1 - 3

Published: July 1, 2016

Language: Английский

---

Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration

Brain, Journal Year: 2017, Volume and Issue: 141(2), P. 459 - 471

Published: Nov. 22, 2017

Survivors of a traumatic brain injury can deteriorate years later, developing atrophy and dementia. Traumatic triggers chronic microglial activation, but it is unclear whether this harmful or beneficial. A successful chronic-phase treatment for might be to target microglia. In experimental models, the antibiotic minocycline inhibits activation. We investigated effect on activation neurodegeneration using PET, MRI, measurement axonal protein neurofilament light in plasma. Microglial was assessed 11C-PBR28 PET. The relationships measures injury, effects disease progression, were structural diffusion plasma light, cognitive assessment. Fifteen patients at least 6 months after moderate-to-severe received either 100 mg orally twice daily no drug, 12 weeks. At baseline, binding increased compared controls cerebral white matter thalamus, levels elevated. MRI damage highest areas greater binding. Minocycline reduced (mean Δwhite = -23.30%, 95% confidence interval -40.9 -5.64%, P 0.018), levels. Faster rates found with higher baseline medicine study, while increasing marker neurodegeneration. These findings suggest that has reparative phase injury.

Language: Английский

---

Blood NfL

Neurology, Journal Year: 2019, Volume and Issue: 93(11)

Published: Aug. 17, 2019

Objective

To examine whether plasma neurofilament light chain (NfL) levels were associated with motor and cognitive progression in Parkinson disease (PD).

Methods

This prospective follow-up study enrolled 178 participants, including 116 PD, 22 multiple system atrophy (MSA), 40 healthy controls. We measured NfL electrochemiluminescence immunoassay. Patients PD received evaluations of cognition at baseline a mean interval 3 years. Changes the Unified Parkinson9s Disease Rating Scale (UPDRS) part III score Mini-Mental State Examination used to assess progression.

Results

Plasma significantly higher MSA group than groups (35.8 ± 6.2, 17.6 2.8, 10.6 2.3 pg/mL, respectively, p < 0.001). In group, elevated patients advanced Hoehn-Yahr stage dementia (p modestly correlated UPDRS scores (r = 0.42, 95% confidence 0.46–0.56, After 3.4 1.2 years, Cox regression analysis adjusted for age, sex, duration, or status showed that risks either 0.029 0.015, respectively).

Conclusions

severity terms both functions PD.

Classification evidence

provides Class evidence level distinguishes from is surrogate biomarker

Language: Английский

---

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD

Neurology, Journal Year: 2019, Volume and Issue: 93(13)

Published: Aug. 31, 2019

Objective

To test the hypothesis that serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), which are an intermediate astrocyte neuron filaments, respectively, clinically useful biomarkers disease activity disability in neuromyelitis optica spectrum disorders (NMOSD).

Methods

Levels GFAP NfL (sGFAP sNfL, respectively) CSF samples were measured healthy controls (HCs) (n = 49; 49 samples), patients with NMOSD 33; 42 102 multiple sclerosis (MS) 53 91 samples) by ultrasensitive single-molecule array assays. Association sGFAP sNfL clinical parameters was determined.

Results

For both NfL, strongly correlated. Both higher than HCs (both p < 0.001). Moreover, MS (median 207.7 vs 121.1 pg/mL, In NMOSD, concentration increased after recent relapse (540.9 152.9 Multivariate analyses indicated associated Expanded Disability Status Scale score (p 0.026 0.001, respectively). Higher sGFAP/sNfL quotient at differentiated from a sensitivity 73.0% specificity 75.8%.

Conclusions

likely to be good disability, is potential diagnostic marker for NMOSD.

Language: Английский

---